Clinuvel Pharmaceuticals (ASX:CUV) expanded its Vallaurix research, development, and innovation center in Singapore with a five-year investment, supported by the Singaporean Economic Development Board, according to a Monday filing with the Australian bourse.
The investment will ensure that ongoing projects in novel pharmaceutical and PhotoCosmetic formulation continue uninterrupted, the filing said.
The company's shares added 2% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.